NASDAQ: INVA · Life Sciences · 2 alerts · CIK 1080014
Share price
$18.49Close, Nov 16
Market cap
$1.31B
Shares outstanding
71.08MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Innoviva, Inc. filings on SEC EDGAR ↗
Innoviva, Inc. reported total revenue of $323.7 million for the nine months ended September 30, 2026, an increase from $296.7 million in the prior year period, driven by higher net product sales. Despite the revenue growth, the company experienced a significant net loss of $73.9 million in the third quarter of 2026, primarily due to $139.5 million in negative fair value adjustments on equity and long-term investments.
Innoviva reported third quarter 2026 financial results, featuring total revenue of $106.1 million and a 45% year-over-year increase in U.S. net product sales to $43.3 million. Despite strong operational income of $42.2 million, the company recorded a net loss of $73.9 million due to a $139.5 million unfavorable change in the fair value of its equity investments, primarily Armata Pharmaceuticals.
Counterparty
Glaxo Group Limited
Term
Q3 2026
“IST delivered another quarter of excellent growth, with U.S. net product sales increasing 45% year-over-year to $43.3 million, keeping us on track to achieve our 2026 guidance of at least $150 million in U.S. net product sales.”
Pavel Raifeld, Chief Executive Officer of Innoviva
“Our durable royalty portfolio, coupled with a strong balance sheet and IST’s expanding revenue base, provides a strong foundation for disciplined, value-accretive capital allocation.”
Pavel Raifeld, Chief Executive Officer of Innoviva